

Press release N° 04/11 from 02.01.2011

### **MOLOGEN AG very successfully completes capital increase**

- **Private placement oversubscribed**
- **Significant amount of new shares subscribed by existing shareholders**
- **Proceeds of EUR 10 million for further development of product pipeline**

Berlin, 02/01/2011 – **Strong interest in shares of MOLOGEN AG: After all of the 1,245,927 new shares were successfully placed, the company can close the international private placement ahead of schedule on February 1<sup>st</sup>, 2011. More than 40% of the subscription rights of existing shareholders were exercised. The shares offered in the context of the private placement were significantly oversubscribed already on the first day. On basis of the issue price of EUR 8.00 per share, MOLOGEN AG will receive approximately EUR 10 million. The proceeds will be used for the further development of the product pipeline.**

„We are very pleased that we were able to successfully complete this capital increase. The proceeds of this capital increase are now offering scope for further development of our product pipeline. After the successes with our colorectal cancer medication MGN1703, we want to take a broader view going into the future and now also test its mode of action in clinical trials for additional cancer indications“, states Dr Matthias Schroff, Research Chairman and Chairman of the Board of MOLOGEN AG. The blockbuster candidate, the colorectal cancer medication MGN1703, is supposed to be licensed this year.

The quirin bank AG was acting as lead manager in this capital increase.

#### **About MOLOGEN AG**

*MOLOGEN AG, a German bio-pharmaceutical company based in Berlin, specializes in the research and development of innovative medicaments based on DNA structures. Activities focus on numerous product developments relevant to the immune system, on the one hand vaccines against serious infections and on the other hand cancer medicaments. MOLOGEN AG is one of the few biotechnology companies worldwide with a well-compatible DNA-based cancer treatment in the clinical development stage.*

*Stock in MOLOGEN AG is listed in the Prime Standard of the German stock exchange (ISIN DE 0006637200).*

**Association memberships:**

BIO Deutschland e.V. | DECHEMA - Gesellschaft für Chemische Technik und Biotechnologie e.V. | Deutsche Industrievereinigung Biotechnologie (DIB) | Stifterverband für die Deutsche Wissenschaft e.V. | Vereinigung deutscher Biotechnologie-Unternehmen (VBU) | Verband Forschender Arzneimittelhersteller e.V. (VFA) | Verband der Chemischen Industrie e.V. (VCI)

MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.

**MOLOGEN AG****PRESS SERVICE**

Prof. Peter W. Hübner  
Head of Corporate Communications

Tel: +49 - 30 - 84 17 88 - 38

Fax: +49 - 30 - 84 17 88 - 50

huebner@mologen.com

**INVESTOR RELATIONS:**

Jörg Petraß

Tel: +49 - 30 - 84 17 88 - 13

Fax: +49 - 30 - 84 17 88 - 50

investor@mologen.com

**External Investor Relations**

Kirchhoff Consult AG

Janina Wismar M.A.

Tel: +49 - 40 - 60 91 86 - 50

Fax: +49 - 40 - 60 91 86 - 16

janina.wismar@kirchhoff.de

**Note**

*This notification represents neither a request nor an offer to submit an offer for the purchase of securities. This is particularly the case in the USA and other countries or jurisdictions where an offer would be unauthorized for the submission of a bid for the purchase or sale without previous registration or authorization. The respective relevant legal provisions concerning securities for these countries and jurisdictions apply. This notification represents neither an offer for the sale of shares without a par value attributed to the owner, nor a request to submit an offer for the purchase of shares without a par value, but rather serves solely to provide information.*

**Risk notice regarding forward-looking statements**

*Certain statements in this report contain forward-looking expressions or corresponding expressions with negation or deviating versions thereof or comparable terminology, these are designated as forward-looking statements. In addition, all information given here that relates to planned or future results from business sectors, financial figures, developments of the financial situation or other financial figures or statistical statements, contain such forward-looking statements. The company advises potential investors to not rely on these forward-looking statements as a prediction of actual future events. The company is not obliged to update these forward-looking statements that only reflect the situation on the day of publication, and rejects any liability therefor.*